Testing a desensitization method during chemotherapy for gynecologic cancers
Tests immune tolerance induction during early chemotherapy in people with gynecologic cancer.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 21 May 2025
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Proactive immune tolerance induction
- Standard Treatment
- Paclitaxel and carboplatin
- Standard premedication (20 mg)
- Reduced premedication (10 mg)
- Reduced premedication (5 mg)
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with a gynecologic cancer who are getting paclitaxel and carboplatin chemotherapy and have never had an allergic reaction to these drugs.
- Age
- 19 years or older
- Sex
- Women only
- Disease stage
- Gynecologic cancer (ovarian, endometrial or cervical) treated with paclitaxel and carboplatin chemotherapy
- Earlier treatment
- No earlier hypersensitivity (allergic-type) reaction to paclitaxel or carboplatin
Main reasons for not taking part
- Does not want to take part voluntarily
- Unsuitable for the trial in the investigator's opinion
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies
- Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin
- Patients who are able to read and voluntarily provide written informed consent
- Aged 19 years or older
Who cannot take part
- Patients who do not wish to participate in this study voluntarily
- Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaContact: Hye-Ryun Kang, MD, PhDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.
Read full original descriptionShow less
The main questions it aims to answer are:
- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles?
Participants will:
* Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
The 6 groups in the trial
- (Trial 1) Proactive immune tolerance induction with 20 mg dexamethasone as premedicationTreatment being tested
Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 20 mg of dexamethasone.
Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Standard premedication (20 mg)
- (Trial 1) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison
Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.
Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)
- (Trial 2) Proactive immune tolerance induction with 10 mg dexamethasone as premedicationTreatment being tested
Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 10 mg of dexamethasone.
Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Reduced premedication (10 mg)
- (Trial 2) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison
Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.
Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)
- (Trial 3) Proactive immune tolerance induction with 5 mg dexamethasone as premedicationTreatment being tested
Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 5 mg of dexamethasone.
Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Reduced premedication (5 mg)
- (Trial 3) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison
Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.
Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer
- Plain-language title
- Testing a desensitization method during chemotherapy for gynecologic cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 October 2026